前列地尔对慢性重型肝炎患者血清TNF-α、IL-8的影响

目的观察前列地尔脂微球载体注射液(Lipo-PGE1)对慢性重型肝炎患者血清肿瘤坏死因子-α(TNF-α)、白细胞介素-8(IL-8)水平的影响。方法采用ELISA法检测44例慢性重型肝炎患者治疗前后血清中TNF-α、IL-8水平的动态变化。结果慢性重型肝炎患者血清TNF-α、IL-8水平明显高于慢性肝炎及健康人(P<0.05~0.01)。Lipo-PGE1治疗组慢性重型肝炎患者TNF-α、IL-8水平明显下降(P<0.05~0.01),死亡率也明显低于一般综合治疗组(P<0.05)。Lipo-PGE1治疗组血清胆红素浓度下降与血清TNF-α、IL-8水平下降呈正相关(P<0.05~0.01)。结论TNF-α、IL-8水平可以反映慢性重型肝炎损伤的程度及判断预后,Lipo-PGE1注射液能改善慢性重型肝炎免疫状态,降低慢性重型肝炎患者血清TNF-α、IL-8的水平,是其治疗慢性重型肝炎的作用机制之一。

Effects of Lipo-PGE1 Injection on Serum INF-α and IL-8 in Patients with Chronic Severe Hapatitis B

Objective To assess the effects of lipo-PGE_1 injection on the serum levels of INF-α and IL-8 in patients with chronic severe hepatitis.Methods Enzyme-liked immunosorbent assay(ELISA) was performed in 44 patients with chronic severe hepatitis to determine the serum levels of TNF-α and IL-8 prior to and post the therapy.Results The serum levels of TNF-α and IL-8 were increased significantly in patients with chronic severe hepatitis compared with the patients with chronic hepatitis and normal control group and decreased obviously after therapy with lipo-PGE_1 compared with before therapy,and the rate of delth were decreased obviously in lipo-PGE_1 therapy group.Conclusion The serum levels of TNF-α and IL-8 can reflect the degree of liver damage in patients with chronic severe hepatitis and guide the assessment of prognosis;Lipo-PGE_1 can correct the immune disorder and treat chronic serere hepatitis by reducing the serum levels of TNF-α and IL-8.